

This abstract was presented at the 2023 DTRF Int'l Desmoid Tumor Research Workshop.

### **Expression of the hexosamine biosynthesis pathway components in desmoid tumors**

Pegah Rahimizadeh<sup>1,2</sup>, Angela Tolwani<sup>3</sup>, Sushama Varma<sup>3</sup>, Mina Farag<sup>4</sup>, Sungmi Jung<sup>4</sup>, Matt van de Rijn<sup>3</sup>, Joanna Przybyl<sup>1,2</sup>

<sup>1</sup> Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada

<sup>2</sup> Department of Surgery, McGill University, Montreal, QC, Canada

<sup>3</sup> Department of Pathology, Stanford University, Stanford, CA, USA

<sup>4</sup> Department of Pathology, McGill University, Montreal, QC, Canada

Cancer cells rewire metabolic pathways and energy production to support the enhanced proliferation, invasion and resistance to treatment. The three main glucose metabolism pathways that support growth of cancer cells are: a) the glycolysis pathway for energy production; b) the pentose phosphate pathway for biomass production; and c) the hexosamine biosynthesis pathway (HBP) for protein glycosylation. It is known that the activation of HBP leads to altered glycosylation of oncogenes, transcription factors and kinases in many types of cancer. These aberrations may lead to increased proliferation and survival of tumor cells, and may be associated with resistance to therapy. A better understanding of the role of HBP in malignancies has the potential for clinical implications. Several studies demonstrated that pharmacological inhibition of GFPT2 (glutamine-fructose-6-phosphate transaminase 2, the first and rate-limiting enzyme in HBP) and OGT (glycosyltransferase that catalyzes the addition of the O-GlcNAc in posttranslational modification of proteins) may exhibit anti-tumorigenic effect both *in vitro* and *in vivo*, and may modulate sensitivity to chemo-, radio- and immunotherapy. Most of these studies focused on carcinomas and the role of HBP in sarcoma has not been studied.

We previously performed a large-scale screening of 260 primary specimens of 33 types of soft tissue lesions. We observed near universal expression of GFPT2 in desmoid type fibromatosis (DTF) in 33 of 34 cases, independent of the mutation type of the *CTNNB1* gene. GFPT2 expression was significantly enriched in DTF compared to other types of tumors (Chi-square test  $p < 0.00001$ ). Gene Set Enrichment Analysis of a previously published 3SEQ transcriptomic dataset composed of DTF and 9 other types of fibrotic lesions identified significant enrichment of other genes implicated in HBP and multiple glycosylation-associated pathways in DTF compared to the other types of fibrotic lesions. To further explore the possible activation of HBP in a larger cohort of DTF, we performed immunohistochemistry to evaluate expression of GFPT2, OGT and the presence of O-GlcNAc modification in tissue microarrays composed of 87 primary and recurrent DTF specimens. This analysis demonstrated GFPT2 expression in the majority of DTF, and the universal expression of OGT and the presence of O-GlcNAc in all archival specimens of DTF. Currently, we work on the characterization of expression of the other key HBP enzymes in DTF.

This study will provide new insights into metabolic reprogramming in DTF. In the future, our study will explore the potential of therapeutic targeting of HBP in DTF. The modulation of glucose metabolism through HBP, either alone or in combination with other treatment modalities, is a

promising direction of research. Our study will offer the first functional exploration of the role of this pathway in DTF.